HealthEquity’s Strong Q3 Performance and Raised Guidance Justify Buy Rating with Significant Upside Potential

In a report released today, Alexander Paris from Barrington reiterated a Buy rating on Healthequity, with a price target of $125.00.

TipRanks Cyber Monday Sale

• Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
• Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Alexander Paris has given his Buy rating due to a combination of factors including HealthEquity’s strong financial performance in the third quarter, which exceeded expectations. The company reported a notable increase in total revenue, driven by significant custodial revenue growth, and an impressive rise in adjusted EBITDA and non-GAAP net income. These results surpassed both the firm’s estimates and the consensus figures, indicating robust operational efficiency and financial health.
Moreover, HealthEquity’s management has raised its full-year guidance, reflecting confidence in continued revenue and margin improvements, supported by strategic investments in technology and security. The company’s shares are trading at attractive multiples compared to its high-growth SaaS peers and its historical averages, suggesting potential for further appreciation. With a leading position in the HSA market and a favorable market environment, HealthEquity is well-positioned for future growth, justifying the reiterated OUTPERFORM rating and a 12-month price target of $125, representing a significant upside potential.

In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $125.00 price target.